Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Syndrome

NCT03708900 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Cushing Syndrome

Interventions

DRUG: LCI699

Sponsor

RECORDATI GROUP